Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes

被引:19
|
作者
Berard, Anick [1 ]
Sheehy, Odile
Kurzinger, Marie-Laure
Juhaeri, Juhaeri
机构
[1] Univ Montreal, Fac Pharm, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada
基金
加拿大健康研究院;
关键词
Triamcinolone; rhinitis; pregnancy; major congenital malformations; small for gestational age; spontaneous abortions; ALLERGIC RHINITIS; CONGENITAL-MALFORMATIONS; ADMINISTRATIVE DATABASES; FETAL-RAT; ACETONIDE; ASTHMA; IMPACT; QUEBEC; DRUGS; BUDESONIDE;
D O I
10.1016/j.jaci.2016.01.021
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Intranasal corticosteroid use during pregnancy has increased over the past decade. Objective: We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was introduced for over-the-counter use in October 2013. Methods: We designed a population-based prospective cohort study. From a cohort of 289,723 pregnancies in Montreal, Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corticosteroid-exposed, and nonexposed women during the first trimester were studied for major congenital malformations (overall and organ specific) and spontaneous abortions and during the second/third trimesters for small-for-gestational age (SGA) newborns. The first trimester is the time window of interest for malformations and spontaneous abortion (organogenesis), and the second/third trimesters are the time windows of interest for SGA (fetal growth). Logistic regression model-based generalized estimating equations were used. Results: Adjusting for potential confounders, use of intranasal triamcinolone during the first trimester of pregnancy was not significantly associated with the risk of overall congenital malformations (odds ratio [OR], 0.88; 95% CI, 0.60-1.28; 31 exposed cases) compared with nonexposure; however, it was associated with the risk of respiratory defects (OR, 2.71; 95% CI, 1.11-6.64; 5 exposed cases). Pregnancy exposure to intranasal triamcinolone was not significantly associated with the risk of spontaneous abortion (OR, 1.04; 95% CI, 0.76-1.43; 50 exposed cases). No association was found between second-or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.79-1.43; 50 exposed cases). Conclusions: Maternal exposure to intranasal triamcinolone during pregnancy was not associated with the risk of SGA/spontaneous abortions/overall malformations. However, it has been shown to increase the risk of respiratory system defects. Chance finding cannot be ruled out.
引用
收藏
页码:97 / +
页数:15
相关论文
共 50 条
  • [1] Intranasal Triamcinolone Use during Pregnancy and the Risk of Adverse Pregnancy Outcomes
    Berard, A. B.
    Sheehy, O. S.
    Kurzinger, M. L. K.
    Juhaeri, J. J.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2015, 103 (05) : 410 - 410
  • [2] Intranasal Triamcinolone Use during Pregnancy and the Risk of Adverse Pregnancy Outcomes
    Berard, Anick
    Sheehy, Odile
    Kurzinger, Marie-Laure
    Juhaeri, Juhaeri
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 255 - 255
  • [3] Use of acetaminophen during pregnancy and risk of adverse pregnancy outcomes
    Rebordosa, Cristina
    Kogevinas, Manolis
    Bech, Bodil H.
    Sorensen, Henrik T.
    Olsen, Jorn
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2009, 38 (03) : 706 - 714
  • [4] Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes
    Berard, Anick
    Zhao, Jin-Ping
    Shui, Irene
    Colilla, Susan
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 500 - 509
  • [5] Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
    Anick Bérard
    Shannon Strom
    Jin-Ping Zhao
    Shashi Kori
    Detlef Albrecht
    [J]. Scientific Reports, 11
  • [6] Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
    Berard, Anick
    Strom, Shannon
    Zhao, Jin-Ping
    Kori, Shashi
    Albrecht, Detlef
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [7] Partner violence during pregnancy and risk of adverse pregnancy outcomes
    Coker, AL
    Sanderson, M
    Dong, B
    [J]. PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2004, 18 (04) : 260 - 269
  • [8] Dihydroergotamine (DHE) Use during Gestation and the Risk of Adverse Pregnancy Outcomes
    Berard, A.
    Sheehy, O.
    Kori, S. H.
    [J]. HEADACHE, 2011, 51 : 39 - 39
  • [9] Dihydroergotamine (DHE) Use during Gestation and the Risk of Adverse Pregnancy Outcomes
    Berard, A.
    Sheehy, O.
    Kori, S.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2011, 91 (05) : 352 - 352
  • [10] Dihydroergotamine (DHE) Use During Gestation and the Risk of Adverse Pregnancy Outcomes
    Berard, Anick
    Kori, Shashidhar
    [J]. HEADACHE, 2012, 52 (07): : 1085 - 1093